Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

References

• GerichJEThe genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivityEndocr Rev19981944915039715377
   PubMed Web of Science ®Google Scholar
• KahnSEThe relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetesDiabetologia200346131912637977
   PubMed Web of Science ®Google Scholar
• StumvollMGoldsteinBJvan HaeftenTWType 2 diabetes: pathogenesis and treatmentLancet200837196312153215618586159
   PubMed Web of Science ®Google Scholar
• GerichJEClinical significance, pathogenesis, and management of postprandial hyperglycemiaArch Intern Med2003163111306131612796066
   PubMed Web of Science ®Google Scholar
• PeterROkoseimeOEReesAOwensDRPostprandial glucose – a potential therapeutic target to reduce cardiovascular mortalityCurr Vasc Pharmacol200971687419149642
   PubMed Web of Science ®Google Scholar
• MonnierLColetteCDunseathGJOwensDRThe loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetesDiabetes Care200730226326917259492
   PubMed Web of Science ®Google Scholar
• TibaldiJImportance of postprandial glucose levels as a target for glycemic control in type 2 diabetesSouth Med J20091021606619077774
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2011Diabetes Care201134Suppl 1S11S6121193625
   PubMed Web of Science ®Google Scholar
• WoerleHJNeumannCZschauSImpact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levelsDiabetes Res Clin Pract200777228028517240473
   PubMed Web of Science ®Google Scholar
• International Diabetes FederationIDF guideline for management of postmeal glucose Available from: http://www.idf.org/webdata/docs/Guideline_PMG_final.pdfAccessed October 26, 2012
   Google Scholar
• CoutinhoMGersteinHCWangYYusufSThe relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 yearsDiabetes Care199922223324010333939
   PubMed Web of Science ®Google Scholar
• LinHJLeeBCHoYLPostprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic populationDiabetes Care20093291721172619502543
   PubMed Web of Science ®Google Scholar
• GallwitzBImplications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelinesDiabetes Care200932Suppl 2S322S32519875573
   PubMed Web of Science ®Google Scholar
• CerielloABortolottiNMotzEMeal-generated oxidative stress in type 2 diabetic patientsDiabetes Care1998219152915339727904
   PubMed Web of Science ®Google Scholar
• CerielloABortolottiNMotzEMeal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemiaMetabolism199948121503150810599980
   PubMed Web of Science ®Google Scholar
• CerielloATabogaCTonuttiLEvidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatmentCirculation2002106101211121812208795
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• International Diabetes FederationIDF guidelines for management of postmeal glucose in patients with diabetes Available from: http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdfAccessed June 6, 2013
   Google Scholar
• RizzoMRizviAASpinasGARiniGBBerneisKGlucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitorsExpert Opin Investig Drugs2009181014951503
   PubMed Web of Science ®Google Scholar
• MeyerCWoerleHJDostouJMWelleSLGerichJEAbnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetesAm J Physiol Endocrinol Metab20042876E1049E105615304374
   PubMed Web of Science ®Google Scholar
• MitrakouAKelleyDMokanMRole of reduced suppression of glucose production and diminished early insulin release in impaired glucose toleranceN Engl J Med1992326122291727062
   PubMed Web of Science ®Google Scholar
• WoerleHJSzokeEMeyerCMechanisms for abnormal postprandial glucose metabolism in type 2 diabetesAm J Physiol Endocrinol Metab20062901E67E7716105859
   PubMed Web of Science ®Google Scholar
• GerichJEPostprandial hyperglycemia and cardiovascular diseaseEndocr Pract200612Suppl 1475116627380
   PubMedGoogle Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1cDiabetes Care200326388188512610053
   PubMed Web of Science ®Google Scholar
• RiddleMUmpierrezGDiGenioAZhouRRosenstockJContributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetesDiabetes Care201134122508251422028279
   PubMed Web of Science ®Google Scholar
• van HaeftenTWPimentaWMitrakouARelative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemiaMetabolism200049101318132511079822
   PubMed Web of Science ®Google Scholar
• CerielloA25 years of progress in type 2 diabetesMedicographia2011332934
   Google Scholar
• CerielloADoes postprandial blood glucose matter and why?Endocrinol Nutr200956Suppl 481120629222
   PubMedGoogle Scholar
• NodeKInoueTPostprandial hyperglycemia as an etiological factor in vascular failureCardiovasc Diabetol200982319402896
   PubMed Web of Science ®Google Scholar
• StandlESchnellOCerielloAPostprandial hyperglycemia and glycemic variability: should we care?Diabetes Care201134Suppl 2S120S12721525442
   PubMed Web of Science ®Google Scholar
• DefronzoRAInsulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Diabetologia20105371270128720361178
   PubMed Web of Science ®Google Scholar
• CerielloACavarapeAMartinelliLThe post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspartDiabet Med200421217117514984453
   PubMed Web of Science ®Google Scholar
• EspositoKGiuglianoDNappoFMarfellaRCampanian Postprandial Hyperglycemia Study GroupRegression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitusCirculation2004110221421915197140
   PubMed Web of Science ®Google Scholar
• HolmanRRHaffnerSMMcMurrayJJEffect of nateglinide on the incidence of diabetes and cardiovascular eventsN Engl J Med2010362161463147620228402
   PubMed Web of Science ®Google Scholar
• GribbleFMManleySELevyJCRandomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166)Diabetes Care20012471221122511423506
   PubMed Web of Science ®Google Scholar
• RazIWilsonPWStrojekKEffects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trialDiabetes Care200932338138619246588
   PubMed Web of Science ®Google Scholar
• CerielloAPostprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer?Diabetes Care200932352152219246590
   PubMed Web of Science ®Google Scholar
• CohenAHortonESProgress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic controlCurr Med Res Opin200723490591717407648
   PubMed Web of Science ®Google Scholar
• GargSKThe role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes – a comprehensive reviewDiabetes Technol Ther2010121112420082581
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
   PubMed Web of Science ®Google Scholar
• AryangatAVGerichJEType 2 diabetes: postprandial hyperglycemia and increased cardiovascular riskVasc Health Risk Manag2010614515520448799
   PubMedGoogle Scholar
• NicolausMBrodlJLinkeRWoerleHJGokeBSchirraJEndogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptyingJ Clin Endocrinol Metab201196122923621047924
   PubMed Web of Science ®Google Scholar
• NeumillerJJDifferential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitorsJ Am Pharm Assoc (2003)200949Suppl 1S16S2919801361
   PubMed Web of Science ®Google Scholar
• VollmerKGardiwalHMengeBAHyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humansJ Clin Endocrinol Metab20099441379138519174495
   PubMed Web of Science ®Google Scholar
• DruckerDJThe biology of incretin hormonesCell Metab20063315316516517403
   PubMed Web of Science ®Google Scholar
• FarillaLBulottaAHirshbergBGlucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human isletsEndocrinology2003144125149515812960095
   PubMed Web of Science ®Google Scholar
• PerfettiRHuiHThe role of GLP-1 in the life and death of pancreatic beta cellsHorm Metab Res20043611–1280481015655712
   PubMed Web of Science ®Google Scholar
• CampbellRKCobbleMEReidTSShomaliMEDistinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapiesJ Fam Pract2010599 Suppl 1S5S920824239
   PubMed Web of Science ®Google Scholar
• MonamiMMarchionniNMannucciEGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trialsEur J Endocrinol2009160690991719318378
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• McCullochDKManagement of persistent hyperglycemia in type 2 diabetes mellitus Available from: http://www.uptodate.com/contents/management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus?source=search_result&search=management+of+persistent+hyperglycemia+in+type+2+diabetes&selectedTitle=1%7E150Accessed October 26, 2012
   Google Scholar
• Byetta® (exenatide) injection [package insert]San Diego, CAAmylin Pharmaceuticals Inc2010
   Google Scholar
• BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]San Diego, CAAmylin Pharmaceuticals Inc2012
   Google Scholar
• Victoza® (liraglutide [rDNA origin] injection) [package insert]Bagsvaerd, DenmarkNovo Nordisk A/S2012
   Google Scholar
• HollanderPAKushnerPType 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitorsPostgrad Med20101223718020463416
   PubMed Web of Science ®Google Scholar
• SchwartzEAKoskaJMullinMPSyoufiISchwenkeDCReavenPDExenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitusAtherosclerosis2010212121722220557887
   PubMed Web of Science ®Google Scholar
• CerveraAWajcbergESriwijitkamolAMechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetesAm J Physiol Endocrinol Metab20082945E846E85218334612
   PubMed Web of Science ®Google Scholar
• ApovianCMBergenstalRMCuddihyRMEffects of exenatide combined with lifestyle modification in patients with type 2 diabetesAm J Med20101235468. e9e1720399326
   PubMed Web of Science ®Google Scholar
• MorettoTJMiltonDRRidgeTDEfficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group studyClin Ther20083081448146018803987
   PubMed Web of Science ®Google Scholar
• GaoYYoonKHChuangLMEfficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylureaDiabetes Res Clin Pract2009831697619019476
   PubMed Web of Science ®Google Scholar
• BrodowsRGQuYJohnsDKimDHolcombeJHQuantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetesCurr Med Res Opin20082451395139718394265
   PubMed Web of Science ®Google Scholar
• BunckMCCornerAEliassonBOne-year treatment with exenatide vs insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stressAtherosclerosis2010212122322920494360
   PubMed Web of Science ®Google Scholar
• SchwartzSLRatnerREKimDDEffect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week studyClin Ther200830585886718555933
   PubMed Web of Science ®Google Scholar
• BuseJBBergenstalRMGlassLCUse of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trialAnn Intern Med2011154210311221138825
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar
• BlevinsTPullmanJMalloyJDURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetesJ Clin Endocrinol Metab20119651301131021307137
   PubMed Web of Science ®Google Scholar
• DiamantMVanGLStranksSOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialLancet201037597332234224320609969
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacConellLEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialLancet2010376973943143920580422
   PubMed Web of Science ®Google Scholar
• TaylorKGurneyKHanJPencekRWalshBTrautmannMExenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 yearsBMC Endocr Disord201111921529363
   PubMed Web of Science ®Google Scholar
• WyshamCBergenstalRMalloyJDURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatideDiabet Med201128670571421434995
   PubMed Web of Science ®Google Scholar
• EdavalathMStephensJWLiraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectivesPatient Prefer Adherence20104616820361006
   PubMed Web of Science ®Google Scholar
• FlintAKapitzaCHindsbergerCZdravkovicMThe once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patientsAdv Ther201128321322621340616
   PubMed Web of Science ®Google Scholar
• SeinoYRasmussenMFZdravkovicMKakuKDose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetesDiabetes Res Clin Pract200881216116818495285
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet2009373966247348118819705
   PubMed Web of Science ®Google Scholar
• KakuKRasmussenMFClausonPSeinoYImproved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetesDiabetes Obes Metab201012434134720380655
   PubMed Web of Science ®Google Scholar
• BuseJBRosenstockJSestiGLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet20093749683394719515413
   PubMed Web of Science ®Google Scholar
• DruckerDJShermanSIGorelickFSBergenstalRMSherwinRSBuseJBIncretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefitsDiabetes Care201033242843320103558
   PubMed Web of Science ®Google Scholar
• WernerUHaschkeGHerlingAWKramerWPharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetesRegul Pept20101642–3586420570597
   PubMedGoogle Scholar
• RatnerRERosenstockJBokaGDose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trialDiabet Med20102791024103220722676
   PubMed Web of Science ®Google Scholar
• RiddleMCAronsonRHomePAdding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Diabetes Care20133692489249623628617
   PubMed Web of Science ®Google Scholar
• PingetMGoldenbergRNiemoellerEMuehlen-BartmerIGuoHAronsonREfficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (Getgoal-P)Diabetes Obes Metab201315111000100723627775
   PubMed Web of Science ®Google Scholar
• RiddleMCForstTAronsonRAdding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)Diabetes Care20133692497250323564915
   PubMed Web of Science ®Google Scholar
• BarnettAHLixisenatide: evidence for its potential use in the treatment of type 2 diabetesCore Evid20116677922022289
   PubMedGoogle Scholar
• FonsecaVAAlvarado-RuizRRaccahDBokaGMiossecPGerichJEEfficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)Diabetes Care20123561225123122432104
   PubMed Web of Science ®Google Scholar
• SeinoYMinKWNiemoellerETakamiARandomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)Diabetes Obes Metab2012141091091722564709
   PubMed Web of Science ®Google Scholar
• RatnerRHanefeldMShamannaPEfficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea ± metformin (GetGoal-S)Diabetologia201154S317
   Web of Science ®Google Scholar
• HorowitzMRaynerCKJonesKLMechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetesAdv Ther20133028110123423907
   PubMed Web of Science ®Google Scholar
• MatthewsJEStewartMWDe BoeverEHPharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetesJ Clin Endocrinol Metab200893124810481718812476
   PubMed Web of Science ®Google Scholar
• RosenstockJReuschJBushMYangFStewartMPotential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosingDiabetes Care200932101880188619592625
   PubMed Web of Science ®Google Scholar
• HassanMEskilssonANilssonCIn vivo dynamic distribution of 131I-glucagon-like peptide-1 (7–36) amide in the rat studied by gamma cameraNucl Med Biol199926441342010382845
   PubMed Web of Science ®Google Scholar
• KastinAJAkerstromVPanWInteractions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrierJ Mol Neurosci2002181–271411931352
   PubMed Web of Science ®Google Scholar
• KastinAJAkerstromVEntry of exendin-4 into brain is rapid but may be limited at high dosesInt J Obes Relat Metab Disord200327331331812629557
   PubMed Web of Science ®Google Scholar
• McCleanPLParthsarathyVFaivreEHolscherCThe diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s diseaseJ Neurosci201131176587659421525299
   PubMed Web of Science ®Google Scholar
• BaggioLLHuangQBrownTJDruckerDJA recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasisDiabetes20045392492250015331566
   PubMed Web of Science ®Google Scholar
• RosenstockJAhrenBChowFCOnce-weekly GLP-1 receptor agonist albiglutide vs titrated prandial lispro added on to titrated basal insulin glargine in type 2 diabetes (T2D) uncontrolled on glargine plus oral agents: similar glycemic control with weight loss and less hypoglycemiaDiabetes201261Suppl 1A15
   Google Scholar
• PratleyREBarnettAHFeinglosMNEfficacy and safety of once-weekly (QW) albiglutide vs once-daily (QD) liraglutide in type 2 diabetes (T2D) inadequately controlled on oral agents: HARMONY 7 trialDiabetes201261Suppl 1
   Google Scholar
• FonsecaVLAhrenBChowFOnce weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar control with weight loss and less hypoglycemiaPoster presented at the 2012 European Association for the Study of Diabetes (EASD) MeetingOctober 1–5, 2012Berlin, Germany2012
   Google Scholar
• FinemanMSCirincioneBBMaggsDDiamantMGLP-1 based therapies: differential effects on fasting and postprandial glucoseDiabetes Obes Metab201214867568822233527
   PubMed Web of Science ®Google Scholar
• AhrenADimasLMiossecPEfficacy and safety of lixisenatide QD morning and evening injections vs placebo in T2DM inadequately controlled on metformin (GetGoal-M)World Diabetes Congress of the International Diabetes FederationDecember 4–8, 2011Dubai, United Arab Emirates2011
   Google Scholar
• KapitzaCForstTCoesterHVPoitiersFRuusPHincelin-MeryAPharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metforminDiabetes Obes Metab201315764264923368510
   PubMed Web of Science ®Google Scholar
• NauckMAKemmeriesGHolstJJMeierJJRapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humansDiabetes20116051561156521430088
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar
• GhatakSBPatelDSShankerNSrivstavaADeshpandeSSPanchalSJAlogliptin: a novel molecule for improving glycemic control in type II diabetes mellitusCurr Diabetes Rev20106641042120879969
   PubMedGoogle Scholar
• BockGDalla ManCMichelettoFThe effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucoseClin Endocrinol (Oxf)201073218919620039889
   PubMed Web of Science ®Google Scholar
• Januvia™ (sitagliptin) tablets [package insert]Whitehouse Station, NJMerck and Co Inc2012
   Google Scholar
• Onglyza™ (saxagliptin) tablets [package insert]Princeton, NJBristol-Myers Squibb Company2011
   Google Scholar
• Tradjenta™ (linagliptin) tablets [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals Inc2011
   Google Scholar
• Del PratoSBarnettAHHuismanHNeubacherDWoerleHJDugiKAEffect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes Obes Metab201113325826721205122
   PubMed Web of Science ®Google Scholar
• RosenstockJAguilar-SalinasCKleinENepalSListJChenRCV181-011 Study InvestigatorsEffect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetesCurr Med Res Opin200925102401241119650754
   PubMed Web of Science ®Google Scholar
• NonakaKKakikawaTSatoAEfficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetesDiabetes Res Clin Pract200879229129817933414
   PubMed Web of Science ®Google Scholar
• IwamotoYTaniguchiTNonakaKDose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitusEndocr J201057538339420332588
   PubMed Web of Science ®Google Scholar
• TaskinenMRRosenstockJTamminenISafety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes Obes Metab2011131657421114605
   PubMed Web of Science ®Google Scholar
• DefronzoRAHissaMNGarberAJThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care20093291649165519478198
   PubMed Web of Science ®Google Scholar
• StenlofKRazINeutelJRavichandranSBerglindNChenRSaxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metforminCurr Med Res Opin201026102355236320804445
   PubMed Web of Science ®Google Scholar
• ChacraARTanGHRavichandranSListJChenRSafety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeksDiab Vasc Dis Res20118215015921562067
   PubMed Web of Science ®Google Scholar
• ChacraARTanGHApanovitchARavichandranSListJChenRSaxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialInt J Clin Pract20096391395140619614786
   PubMed Web of Science ®Google Scholar
• BarnettAHCharbonnelBDonovanMFlemingDChenREffect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metforminCurr Med Res Opin201228451352322313154
   PubMed Web of Science ®Google Scholar
• MinerviniGCharbonnelBBarnettAHMonyakJIqbalNEfficacy and safety of saxagliptin in combination with insulin in patients with long-standing type 2 diabetesAbstract presented at the American Diabetes Association 72nd Scientific SessionsJune 8–12, 2012Philadelphia, PA2012
   Google Scholar
• VilsbollTRosenstockJYki-JarvinenHEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesDiabetes Obes Metab201012216717720092585
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHDuran-GarciaSPinnettiSEfficacy and safety of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetesAbstract presented at the American Diabetes Association 72nd Scientific SessionsJune 8–12, 2012Philadelphia, PA2012
   Google Scholar
• ViereckCBoudesPAn analysis of the impact of FDA’s guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical developmentContemp Clin Trials201132332433221266202
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEFerranniniEChanges in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapyDiabetes Care201033473073220067974
   PubMed Web of Science ®Google Scholar
• DerosaGMaffioliPFerrariIEffects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patientsHorm Metab Res201042966366920560108
   PubMed Web of Science ®Google Scholar
• GarberAJFoleyJEBanerjiMAEffects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaDiabetes Obes Metab200810111047105618284434
   PubMed Web of Science ®Google Scholar
• LukashevichVKozlovskiPFoleyJKothnyWVildagliptin combined with insulin reduces HbA_1cwithout increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitusAbstract presented at the American Diabetes Association 72nd Scientific SessionsJune 8–12, 2012Philadelphia, PA2012
   Google Scholar
• CovingtonPChristopherRDavenportMPharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesClin Ther200830349951218405788
   PubMed Web of Science ®Google Scholar
• SeinoYFujitaTHiroiSHirayamaMKakuKEfficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension studyCurr Med Res Opin20112791781179221806314
   PubMed Web of Science ®Google Scholar
• PattziHMPitaleSAlpizarMDutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trialDiabetes Obes Metab201012434835520380656
   PubMed Web of Science ®Google Scholar
• MoralesJThe pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitorsPostgrad Med2011123618920122104467
   PubMed Web of Science ®Google Scholar
• DefronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellLEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyCurr Med Res Opin200824102943295218786299
   PubMed Web of Science ®Google Scholar
• SulistioMCarothersCMangatMLujanMOliverosRChiltonRGLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effectsCurr Atheroscler Rep2009112939919228481
   PubMed Web of Science ®Google Scholar
• PencekRBlickensderferALiYBrunellSAndersonPExenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass indexPostgrad Med20121244213222913891
   PubMed Web of Science ®Google Scholar
• PencekRBrunellSLiYHoogwerfBJMaloneJExenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medicationsPostgrad Med20121244334022913892
   PubMed Web of Science ®Google Scholar
• GreenJBThe dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safetyPostgrad Med20121244546122913894
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes Aailable from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/%20Guidances/UCM071627.pdfAccessed October 26, 2012
   Google Scholar
• AhmadSRSwannJExenatide and rare adverse eventsN Engl J Med2008358181970197118456920
   PubMed Web of Science ®Google Scholar
• EngelSSWilliams-HermanDEGolmGTSitagliptin: review of preclinical and clinical data regarding incidence of pancreatitisInt J Clin Pract201064798499020412332
   PubMed Web of Science ®Google Scholar
• ElashoffMMatveyenkoAVGierBElashoffRButlerPCPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesGastroenterology2011141115015621334333
   PubMed Web of Science ®Google Scholar
• DruckerDJShermanSIBergenstalRMBuseJBThe safety of incretin-based therapies – review of the scientific evidenceJ Clin Endocrinol Metab20119672027203121734003
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDArnoldCKUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurr Med Res Opin20092541019102719278373
   PubMed Web of Science ®Google Scholar
• GargRChenWPendergrassMAcute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysisDiabetes Care201033112349235420682680
   PubMed Web of Science ®Google Scholar
• ButlerPCDrySElashoffRGLP-1-based therapy for diabetes: what you do not know can hurt youDiabetes Care201033245345520103562
   PubMed Web of Science ®Google Scholar
• BarzilaiNGuoHMahoneyEMEfficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialCurr Med Res Opin20112751049105821428727
   PubMed Web of Science ®Google Scholar
• PanCYYangWTouCGause-NilssonIZhaoJEfficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trialDiabetes Metab Res Rev201228326827522081481
   PubMed Web of Science ®Google Scholar
• ForstTUhlig-LaskeBRingARitzhauptAGraefe-ModyUDugiKAThe oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitusDiabetes Obes Metab201113654255021352464
   PubMed Web of Science ®Google Scholar
• SeckTNauckMShengDSafety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInt J Clin Pract201064556257620456211
   PubMed Web of Science ®Google Scholar
• StenlofKRazINeutelJRavichandranSBerglindNChenRSaxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metforminCurr Med Res Opin201026102355236320804445
   PubMed Web of Science ®Google Scholar
• FonsecaVZhuTKaryekarCHirshbergBAdding saxagliptin to extended-release metformin vs uptitrating metformin dosageDiabetes Obes Metab201214436537122192246
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab200911215716619125777
   PubMed Web of Science ®Google Scholar